PUBLISHER: The Business Research Company | PRODUCT CODE: 1947027
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947027
Pulmonary drug delivery devices are inhalation devices designed to administer medications directly to the lungs. These devices enable targeted drug delivery for treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, pulmonary delivery allows for the systemic absorption of drugs such as insulin and pain medications.
The primary types of pulmonary drug delivery devices include dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers dispense a measured dose of medication in a fine, dry powder form that the patient inhales directly into their lungs. These devices are used for conditions such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and others. They are distributed through channels such as retail pharmacies, hospital pharmacies, and e-commerce.
Tariffs are impacting the pulmonary drug delivery devices market by increasing costs of imported plastics, electronic sensors, microvalves, drug canisters, and precision molding equipment used in inhalers and nebulizers. Pharmaceutical and medical device manufacturers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces cost pressure on large-scale device manufacturing. These tariffs are raising device prices and affecting market accessibility. However, they are also promoting regional manufacturing, local component sourcing, and innovation in cost-effective and reusable pulmonary delivery systems.
The pulmonary drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides pulmonary drug delivery devices market statistics, including pulmonary drug delivery devices industry global market size, regional shares, competitors with a pulmonary drug delivery devices market share, detailed pulmonary drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drug delivery devices industry. This pulmonary drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pulmonary drug delivery devices market size has grown strongly in recent years. It will grow from $52.8 billion in 2025 to $56.49 billion in 2026 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing prevalence of respiratory diseases, rising use of inhalation therapies, expansion of asthma and copd treatment programs, improvements in inhaler design technologies, growing awareness of pulmonary drug delivery.
The pulmonary drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising adoption of digital health integrated inhalers, expansion of home-based respiratory care, growing focus on non-invasive drug delivery, continued innovation in inhalation technologies. Major trends in the forecast period include increasing adoption of smart and connected inhaler devices, rising demand for targeted pulmonary drug delivery, growing use of mesh and ultrasonic nebulizers, expansion of combination drug-device products, enhanced focus on patient adherence.
The rising prevalence of respiratory disorders is expected to drive the growth of the pulmonary drug delivery devices market moving forward. Respiratory disorders are conditions that affect the lungs and airways, impairing normal respiration. The prevalence of these disorders is increasing due to factors such as higher levels of air pollution, rising smoking rates, urbanization, climate change, and an aging population. Pulmonary drug delivery devices are crucial in managing respiratory disorders, as they enable direct delivery of medications to the lungs for faster and more effective treatment. For instance, in May 2025, according to the US National Center for Health Statistics (via the CDC), the age-adjusted prevalence of diagnosed COPD among adults aged 18 and older in 2023 was 3.8 percent, reflecting an upward trend from previous years. Therefore, the increasing prevalence of COPD is driving the growth of the pulmonary drug delivery devices market.
Major companies in the pulmonary drug delivery devices market are developing innovative products, such as small-volume nebulizers, to better serve customers with advanced features. A small-volume nebulizer (SVN) is a medical device used to deliver liquid medication in the form of an aerosolized mist to patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For instance, in May 2024, Medline Industries, LP, a US-based healthcare company, launched the Hudson RCI TurboMist small-volume nebulizer. This groundbreaking device is designed to deliver medication treatments quickly, in as little as three minutes. The innovative nebulizer can dispense 2.5 times more medication per minute compared to standard nebulizers, reducing treatment times by about 70%. This increase in medication delivery significantly reduces treatment times, benefiting healthcare providers by optimizing patient throughput and enhancing the patient experience by shortening the duration of therapy sessions.
In January 2025, Molex LLC, a US-based electronics and manufacturing company, acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Phillips Medisize, Molex's contract development and manufacturing arm (CDMO), strengthened its inhalation drug-delivery capabilities, enabling an expanded portfolio of combination products and device development. Vectura Group Ltd. is a UK-based pharmaceutical technology company specializing in pulmonary drug delivery devices.
Major companies operating in the pulmonary drug delivery devices market are Medtronic plc, Air Liquide S.A., Becton Dickinson And Company, Koninklijke Philips N.V., Medline Industries Inc., ResMed Inc., Dragerwerk AG And Co. KGaA, Smiths Group plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Teleflex Incorporated, Fisher And Paykel Healthcare Limited, Invacare Corporation, Vyaire Medical Inc., Inogen Inc., Drive DeVilbiss Healthcare Inc., Hovione, Hamilton Medical AG, GaleMed Corporation, Allied Healthcare Products Inc., Precision Medical Inc., Salter Labs Inc.
North America was the largest region in the pulmonary drug delivery devices market in 2025. The regions covered in the pulmonary drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pulmonary drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The pulmonary drug delivery devices market consists of sales of jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pulmonary Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pulmonary drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pulmonary drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.